In vitro susceptibility of nondermatophyte molds isolated from onycomycosis to antifungal drugs

Journal of Chemotherapy

Volumn 21, Issue 4, 2009, Pages 403-407

  Trovato, L ^a   Rapisarda, M F ^a   Greco, A M ^a   Galata F ^a   Oliveri, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antifungal agent; CLSI; Nondermatophyte molds; Onychomycosis; Susceptibility

Indexed keywords

ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROXOLAMINE; FENTICONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TERBINAFINE; TIOCONAZOLE;

ACREMONIUM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; ASPERGILLUS OCHRACEUS; ASPERGILLUS TERREUS; BROTH DILUTION; FUNGAL STRAIN; FUNGUS; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONDERMATOPHYTE MOLD; NONHUMAN; PENICILLIUM; SCOPULARIOPSIS BREVICAULIS; TOENAIL ONYCHOMYCOSIS;

EID: 70349203798     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.4.403     Document Type: Article

References (24)

1. Elewski BE, Elgart ML, Jacobs PH, Lesher JL, Scher RK. Guidelines of care for superficial mycotic infections of the skin: onychomycosis. J Amer Acad Derm 1996; 34: 116-121. (Pubitemid 26043936)
2. Seebacher C, Brasch J, Abeck D, et al. Onychomycosis. Mycoses 2007; 50: 321-327
3. Araújo AJG, Bastos OMP, Souza MAJ, Oliveira JC. Onychomycosis caused by emergent fungi: clinical analysis, diagnosis and revision. An Bras Dermatol 2003; 78: 445-455.
4. Gupta AK, Ryder JE, Summerbell RC. Onychomycosis: classification and diagnosis. J Drugs Dermatol 2004; 3: 51-56.
5. Haneke E. Fungal infections of the nail. Semin Dermatol 1991;10:41-53.
6. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000; 42: 217-224. (Pubitemid 30469618)
7. Melody R, Vander S, Maher MB, Mahmoud AG. The role of nondermatophyte molds in onychomycosis: diagnosis and treatment. Dermatologic Therapy 2002; 15: 89-98. (Pubitemid 34832662)
8. Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, et al. Fungal nail diseases: a guide to good practice (report of a working group of the British society for medical mycology). Br Med J 1995; 311: 1277-1281
9. Veer P, Patwardhan NS, Damle AS. Study of onycomycosis: prevailing fungi and partern of infection. Indian J Med Microbiol 2007; 25: 53-56 (Pubitemid 46466022)
10. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003; 148: 402-410.
11. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-544.
12. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19: 21-29. (Pubitemid 40268136)
13. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open label study of the efficacy and safety of cicloprox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001; 68(2): 17-22.
14. Gupta AK. Onychomycosis in the elderly. Drugs Aging 2000; 16: 397-407.
15. Marty JPL. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol 1995; 4 (1): 17-21.
16. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994;13(43): 16-21. (Pubitemid 24203329)
17. de Hoog GS, Guarro J, Gene' J, Figueras MJ, eds. Hyphomycetes: explanatory chapters, and keys to the genera. In: Atlas of Clinical Fungi, 2th ed. Baarn: Centraalbureau vor Schimmelcultures. 2000: 361.
18. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standards. NCCLS document M38-A. National Committee for Clinical Laboratory Standards. Wayne, Pa.
19. NCCLS/CLSI. 2002. Reference method for broth dilution susceptibility testing of yeast. Approved standard, 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Ellis DH. Diagnosis of onychomycosis made simple. J Am Acad Dermatol 1990; 40: 3-8.
21. Borkowski P, Williams M, Holewinski J, et al. Onychomycosis: an analysis of 50 cases and a comparison of diagnostic techniques. J Am Podiatr Med Assoc 2002; 91: 351-355
22. Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117: 16-19.
23. Piérard GE, Piérard-Franchimont C, Arrese JE. The boosted antifungal topical treatment (BATT) for onycomycosis. Med Mycol 2000; 38: 391-392. (Pubitemid 30802049)
24. Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology 2004; 209(2):104-110